Neurological improvement in patients with chronic spinal cord injury treated with leuprolide acetate, an agonist of GnRH

13Citations
Citations of this article
14Readers
Mendeley users who have this article in their library.

Abstract

It has been reported that gonadotropin-releasing hormone (GnRH), and its analogue leuprolide acetate (LA), have neurotrophic properties; particularly in the regeneration of injured spinal cord in animal models and in the case of a patient with spinal cord injury (SCI). The aim of this study was to establish whether treatment with LA improves sensitivity, motor activity and independence in patients with chronic SCI. Patients were treated LA once a month for six months. They were evaluated at the beginning and at the end of treatment; using a sensitivity and motor impairment scale, according to the American Spinal Injury Association (ASIA), and grade of independence scale; employing the spinal cord independence measure (SCIM). Statistical analysis showed a significant improvement in the ASIA sensory score and the SCIM score when comparing the initial versus final evaluation after six months of LA administration. Some patients showed an increase in frequency of bowel movements. Treatment with LA induces improvements in sensitivity, motor activity and independence in patients with chronic SCI. One advantage of this protocol is that it is a non-invasive method of easy and safe application, with few side effects.

Cite

CITATION STYLE

APA

Quintanar, J. L., Díaz-Galindo, C., Calderón-Vallejo, D., Hernández-Jasso, I., Rojas, F., Medina-Aguiñaga, D., & Olvera-Sandoval, C. (2018). Neurological improvement in patients with chronic spinal cord injury treated with leuprolide acetate, an agonist of GnRH. Acta Neurobiologiae Experimentalis, 78(4), 352–357. https://doi.org/10.21307/ane-2018-034

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free